Global Diabetic Macular Edema Treatment Market, By Indication Type (Diffuse Diabetic Macular Edema and Focal Diabetic Macular Edema), Treatment Type (Vascular Endothelial Growth Factor (VEGF), Corticosteroids, Laser Photocoagulation Therapy and Other Off-Label Drugs), Drug Delivery (Intravitreal Injections and Intravitreal Implants), End User (Hospitals, Clinics and Home Care), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights Global Diabetic Macular Edema Treatment Market
Diabetic macular edema treatment market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 3.65% in the above mentioned forecast period and would likely to reach an estimated value of 63.33 million by 2029. The growing diabetic population which causes diabetic macular edema in patients, will contribute to the growth of the diabetic macular edema treatment market.
Macular edoema is a condition in which fluid and proteins accumulate on or under the macula of the eye, causing swelling. A person's central eye vision becomes distorted as a result of such swelling. Cystoids macular edoema (CME) and diabetic macular edoema (DME) are the two types of macular edoema (DME). Diabetic macular edoema is the leading cause of vision loss in diabetic retinopathy patients. Diabetes patients are said to have a 10% chance of developing the disease during their lifetime.
In the forecast period of 2022-2029, new and innovative research and development for the treatment of diabetic macular edoema will most likely accelerate the growth of the diabetic macular edoema treatment market. On the other hand, advancements in ophthalmic surgery techniques and pharmaceutical companies' research and development investment will further boost various opportunities, leading to the growth of the diabetic macular edoema treatment market during the forecast period.
Other factors driving the growth of the global diabetic macular edoema treatment market include significant research and development investment by pharmaceutical companies and advancements in ophthalmic surgery techniques.
However, high medical costs for patients and frequent visits to physicians are likely to hamper the growth of the diabetic macular edoema treatment market during the forecast period. Less awareness will further challenge the market in the forecast period mentioned above.
This diabetic macular edema treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the diabetic macular edema treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Diabetic Macular Edema Treatment Market Scope and Market Size
Diabetic macular edema treatment market is segmented on the basis of indication type, treatment type, drug delivery and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- Based on indication type, the diabetic macular edema treatment market is segmented into diffuse diabetic macular edema and focal diabetic macular edema.
- On the basis of treatment type, the diabetic macular edema treatment market is segmented into vascular endothelial growth factor (VEGF), corticosteroids, laser photocoagulation therapy, and other off-label drugs.
- On the basis of drug delivery, the diabetic macular edema treatment market is segmented into intravitreal injections and intravitreal implants.
- Diabetic macular edema treatment market has also been segmented based on the end user into hospitals, clinics and home care.
Diabetic Macular Edema treatment Market Country Level Analysis
Diabetic macular edema treatment market is analyzed and market size information is provided by the country, basis of indication type, treatment type, drug delivery and end user as referenced above.
The countries covered in the diabetic macular edema treatment market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the diabetic macular edema treatment market due to the presence of major key players, increasing the penetration of episodic treatments, increasing number of patients with type 2 diabetes and the presence of a top-tier photocoagulation laser. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector, and growing government support. The presence of major and domestic manufacturers of photocoagulation lasers will further contribute to the market growth.
The country section of the diabetic macular edema treatment market report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Diabetic macular edema treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to diabetic macular edema treatment market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the diabetic macular edema treatment market in the growth period.
Competitive Landscape and Global Diabetic Macular Edema Treatment Market Share Analysis
Diabetic macular edema treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to diabetic macular edema treatment market research.
Some of the major players operating in the diabetic macular edema treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, Alimera Sciences, ALLERGAN, Regeneron Pharmaceuticals Inc., Pfizer Inc., Kubota Pharmaceutical Holdings Co. Ltd., Oculis, Bayer AG, Bausch & Lomb Incorporated, The National Eye Institute, Medytox, Smith+Nephew, Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., LGM Pharma., Lannett and NorthStar Rx LLC, among others.
SKU-